BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34051337)

  • 1. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
    Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
    Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
    D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
    Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
    Pham QT; Oue N; Sekino Y; Yamamoto Y; Shigematsu Y; Sakamoto N; Sentani K; Uraoka N; Yasui W
    Oncology; 2018; 95(5):297-308. PubMed ID: 30134247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
    Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
    FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian cancer cells.
    Zhao Y; Tao F; Jiang J; Chen L; Du J; Cheng X; He Q; Zhong S; Chen W; Wu X; Ou R; Xu Y; Tang KF
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.
    Xiong J; Zhang X; Zhang Y; Wu B; Fang L; Wang N; Yi H; Chang N; Chen L; Zhang J
    Exp Cell Res; 2020 Nov; 396(1):112288. PubMed ID: 32941808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNA SH3PXD2A-AS1 Promotes Cell Progression Partly Through Epigenetic Silencing P57 and KLF2 in Colorectal Cancer.
    Ma Z; Peng P; Zhou J; Hui B; Ji H; Wang J; Wang K
    Cell Physiol Biochem; 2018; 46(6):2197-2214. PubMed ID: 29734178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
    Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
    BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
    Lee CC; Yang WH; Li CH; Cheng YW; Tsai CH; Kang JJ
    Cancer Lett; 2016 Jul; 376(2):211-7. PubMed ID: 27060206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.
    Hu T; Weng S; Tang W; Xue R; Chen S; Cai G; Cai Y; Shen X; Zhang S; Dong L
    PLoS One; 2015; 10(5):e0125281. PubMed ID: 25933218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
    Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
    Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
    Chen F; Xu G; Tian W; Gou S
    Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STIP1 knockdown suppresses colorectal cancer cell proliferation, migration and invasion by inhibiting STAT3 pathway.
    Xia Y; Chen J; Liu G; Huang W; Wei X; Wei Z; He Y
    Chem Biol Interact; 2021 May; 341():109446. PubMed ID: 33766539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of Girdin suppresses the malignant behavior of colorectal carcinoma cells.
    Lu J; Zhang L; Zhou H; Du Z; Zhang G
    Oncol Rep; 2018 Aug; 40(2):887-894. PubMed ID: 29989653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.
    Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW
    Front Immunol; 2020; 11():657. PubMed ID: 32477324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
    Kumbrink J; Li P; Pók-Udvari A; Klauschen F; Kirchner T; Jung A
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stemness and immune evasion conferred by the TDO2-AHR pathway are associated with liver metastasis of colon cancer.
    Miyazaki T; Chung S; Sakai H; Ohata H; Obata Y; Shiokawa D; Mizoguchi Y; Kubo T; Ichikawa H; Taniguchi H; Aoki K; Soga T; Nakagama H; Okamoto K
    Cancer Sci; 2022 Jan; 113(1):170-181. PubMed ID: 34714577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression.
    Ye M; He Y; Lin H; Yang S; Zhou Y; Zhou L; Zhong J; Lu G; Zheng J; Xue ZX; Cai ZZ
    Oncol Rep; 2017 May; 37(5):2955-2963. PubMed ID: 28393252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.
    Fonseca AS; Ramão A; Bürger MC; de Souza JES; Zanette DL; de Molfetta GA; de Araújo LF; de Barros E Lima Bueno R; Aguiar GM; Plaça JR; Alves CP; Dos Santos ARD; Vidal DO; Silva GEB; Panepucci RA; Peria FM; Feres O; da Rocha JJR; Zago MA; Silva WA
    BMC Cancer; 2021 Mar; 21(1):207. PubMed ID: 33648461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.